The program on the surgical control of the hyperlipidemias: A status report

Henry Buchwald; R. B. Moore; J. P. Matts; J. M. Long; R. L. Varco; G. S. Campbell; M. B. Pearce; A. E. Yellin; D. H. Blankenhorn; W. L. Holmes; R. D. Smink; H. S. Sawin

The program on the surgical control of the hyperlipidemias: A status report

Henry Buchwald, R. B. Moore, J. P. Matts, J. M. Long, R. L. Varco, G. S. Campbell, M. B. Pearce, A. E. Yellin, D. H. Blankenhorn, W. L. Holmes, R. D. Smink, H. S. Sawin

Surgery

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

The Program on Surgical Control of the Hyperlipidemias (POSCH) is a multicentered secondary coronary heart disease intervention trial utilizing maximal plasma lipid reduction as achieved by the partial ileal bypass operation. With over 500 patients recruited into this trial at present, the 4-year sequential lipid changes are statistically highly significant and include an approximate 30% plasma total cholesterol and 40% low density lipoprotein (LDL)-cholesterol reduction, with a slight increase in the high density lipoprotein (HDL)-cholesterol and a marked increase in the HDL-cholesterol:LDL-cholesterol ratio of about 75% or higher. A definite answer to the lipid-atherosclerosis theory corollary - whether a decrease in the plasma cholesterol engenders a reduction in the incidence or severity of atherosclerotic cardiovascular disease - can be expected from these marked lipid changes in POSCH.

Original language	English (US)
Pages (from-to)	654-662
Number of pages	9
Journal	Surgery
Volume	92
Issue number	4
State	Published - 1982

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{0e4d41bf2a794b4ca555fb7d9e10aaac,

title = "The program on the surgical control of the hyperlipidemias: A status report",

abstract = "The Program on Surgical Control of the Hyperlipidemias (POSCH) is a multicentered secondary coronary heart disease intervention trial utilizing maximal plasma lipid reduction as achieved by the partial ileal bypass operation. With over 500 patients recruited into this trial at present, the 4-year sequential lipid changes are statistically highly significant and include an approximate 30% plasma total cholesterol and 40% low density lipoprotein (LDL)-cholesterol reduction, with a slight increase in the high density lipoprotein (HDL)-cholesterol and a marked increase in the HDL-cholesterol:LDL-cholesterol ratio of about 75% or higher. A definite answer to the lipid-atherosclerosis theory corollary - whether a decrease in the plasma cholesterol engenders a reduction in the incidence or severity of atherosclerotic cardiovascular disease - can be expected from these marked lipid changes in POSCH.",

author = "Henry Buchwald and Moore, {R. B.} and Matts, {J. P.} and Long, {J. M.} and Varco, {R. L.} and Campbell, {G. S.} and Pearce, {M. B.} and Yellin, {A. E.} and Blankenhorn, {D. H.} and Holmes, {W. L.} and Smink, {R. D.} and Sawin, {H. S.}",

year = "1982",

language = "English (US)",

volume = "92",

pages = "654--662",

journal = "Surgery",

issn = "0039-6060",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - The program on the surgical control of the hyperlipidemias

T2 - A status report

AU - Buchwald, Henry

AU - Moore, R. B.

AU - Matts, J. P.

AU - Long, J. M.

AU - Varco, R. L.

AU - Campbell, G. S.

AU - Pearce, M. B.

AU - Yellin, A. E.

AU - Blankenhorn, D. H.

AU - Holmes, W. L.

AU - Smink, R. D.

AU - Sawin, H. S.

PY - 1982

Y1 - 1982

N2 - The Program on Surgical Control of the Hyperlipidemias (POSCH) is a multicentered secondary coronary heart disease intervention trial utilizing maximal plasma lipid reduction as achieved by the partial ileal bypass operation. With over 500 patients recruited into this trial at present, the 4-year sequential lipid changes are statistically highly significant and include an approximate 30% plasma total cholesterol and 40% low density lipoprotein (LDL)-cholesterol reduction, with a slight increase in the high density lipoprotein (HDL)-cholesterol and a marked increase in the HDL-cholesterol:LDL-cholesterol ratio of about 75% or higher. A definite answer to the lipid-atherosclerosis theory corollary - whether a decrease in the plasma cholesterol engenders a reduction in the incidence or severity of atherosclerotic cardiovascular disease - can be expected from these marked lipid changes in POSCH.

AB - The Program on Surgical Control of the Hyperlipidemias (POSCH) is a multicentered secondary coronary heart disease intervention trial utilizing maximal plasma lipid reduction as achieved by the partial ileal bypass operation. With over 500 patients recruited into this trial at present, the 4-year sequential lipid changes are statistically highly significant and include an approximate 30% plasma total cholesterol and 40% low density lipoprotein (LDL)-cholesterol reduction, with a slight increase in the high density lipoprotein (HDL)-cholesterol and a marked increase in the HDL-cholesterol:LDL-cholesterol ratio of about 75% or higher. A definite answer to the lipid-atherosclerosis theory corollary - whether a decrease in the plasma cholesterol engenders a reduction in the incidence or severity of atherosclerotic cardiovascular disease - can be expected from these marked lipid changes in POSCH.

UR - http://www.scopus.com/inward/record.url?scp=0020284349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020284349&partnerID=8YFLogxK

M3 - Article

C2 - 6750834

AN - SCOPUS:0020284349

SN - 0039-6060

VL - 92

SP - 654

EP - 662

JO - Surgery

JF - Surgery

IS - 4

ER -

The program on the surgical control of the hyperlipidemias: A status report

Abstract

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this